Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors

Inclusion Criteria:

Confirmed advanced (unresectable and/or metastatic) solid tumor: gastric cancer (including gastroesophageal junction cancer), esophageal cancer, biliary tract cancer, or pancreatic ductal adenocarcinoma
Participants who experienced Adverse Events (AEs) due to previous anticancer therapies must have recovered to < Grade 1 or baseline
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy
Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
Participants with a history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable
Received and progressed on or after 1 or 2 prior lines of therapy

Exclusion Criteria:

Active severe digestive disease
History of major cardiovascular diseases
History of acute myocardial infarction; unstable angina; stroke or transient ischemic attack within 6 months prior to the first dose of study intervention
Cardiac pacemaker use
Diabetes or hypertension that cannot be controlled by medication
HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Received prior systemic anticancer therapy including investigational agents within 4 weeks before study intervention
Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
Known additional malignancy that is progressing or has required active treatment within the past 2 years
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Active infection requiring systemic therapy
Have not adequately recovered from major surgery or have ongoing surgical complications